Ligand Pharmaceuticals Inc. (Nasdaq:LGND) announced that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.

LCA-Vision Inc. (NASDAQ:LCAV) reported that 10,891 procedures were performed during the fourth quarter of 2010, compared with 11,718 procedures (68 vision centers) during the fourth quarter of 2009. Same-store procedures (54 vision centers) increased by 6% year-over-year from 10,241 procedures during the fourth quarter of 2009.